NCT03250676
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Endocrine (Hormone Therapy
Key Eligibility Criteria:
Gender: Female
Age: 18 Years and older (Adult), Senior)
Location of Metastases:
Additional Notes: Must have ER+ tumor(s)
Exclusions: Patients with IBC
https://ClinicalTrials.gov/show/NCT03250676